There are 2789 resources available
Vision for the future
Presenter: Johann de Bono
Session: Janssen - A Decade’s Perspective on Advances in Prostate Cancer
Resources:
Webcast
Close of meeting
Presenter: Laura-Maria Krabbe
Session: Janssen - A Decade’s Perspective on Advances in Prostate Cancer
Resources:
Webcast
Welcome and Introductions
Presenter: Andrea Necchi
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
Recurrence Post-Radical Resection: Are Systemic Therapies the Solution to Optimize Patient Outcomes?
Presenter: Andrea Necchi
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
Biomarkers: Are We Ready to Use Them in Routine Clinical Practice?
Presenter: Matthew Galsky
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
QoL: Is It a Key Endpoint in the Adjuvant Setting?
Presenter: Matthew Galsky
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
Clinical Cases Discussion (Cisplatin-eligible case; Cisplatin-ineligible case)
Presenter: Matthew Galsky
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
Live Q&A session
Presenter: James Catto
Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
Resources:
Webcast
Introduction and welcome
Presenter: Egbert F. Smit
Session: AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease
Resources:
Webcast
Optimising patient outcomes with adjuvant Osimertinib: Improving patient identification through non-smoking related NSCLC screening and EGFR reflex testing
Presenter: Fan Yang
Session: AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease
Resources:
Webcast